NEULANDLAB23,800.00

Neuland Laboratories Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABLAURUSLABSNHNATCOPHARMLALPATHLABSAILIFECOHANCEASTERDMMcap ₹30,703 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
NEULANDLAB
FY26
DIVISLAB
FY26
LAURUSLABS
FY26
NH
FY26
Peer
Median
Valuation — at last close
P/E83.89×97.31×117.94×47.97×97.31× -14%
P/B16.38×14.89×19.31×8.57×14.89× +10%
EV/EBITDA53.65×72.47×60.27×26.33×60.27× -11%
Market Cap₹30,703 Cr₹2.49L Cr₹1.05L Cr₹38,888 Cr₹1.05L Cr -71%
Growth
Revenue CAGR 3Y19.31%10.78%4.09%20.39%10.78% +79%
Revenue CAGR 5Y16.64%8.67%7.19%25.05%8.67% +92%
Net Income CAGR 3Y30.57%12.09%3.91%9.94%9.94% +208%
Revenue YoY (latest Q)119.15%27.80%29.10%78.05%29.10% +309%
Net Income YoY (latest Q)962.40%65.50%123.94%5.37%65.50% +1369%
Profitability
EBITDA Margin28.40%32.59%26.09%20.47%26.09% +9%
Net Income Margin17.99%24.32%13.07%10.21%13.07% +38%
Return on Common Equity19.42%15.32%16.36%17.75%16.36% +19%
Return on Capital Employed21.75%16.55%18.87%10.98%16.55% +31%
Return on Assets12.42%12.82%8.47%6.46%8.47% +47%
Credit & Quality
Total Debt/Equity0.10×0.00×0.44×1.07×0.44× -77%
Interest Coverage20.16×129.48×7.60×4.80×7.60× +165%
Scale — latest FY
Revenue / Total Income₹2,023 Cr₹10,560 Cr₹6,813 Cr₹7,896 Cr₹7,896 Cr -74%
Net Income₹364 Cr₹2,568 Cr₹890 Cr₹806 Cr₹890 Cr -59%
Total Assets₹2,930 Cr₹20,033 Cr₹10,511 Cr₹12,474 Cr₹12,474 Cr -77%
EPS₹283.71₹96.75₹16.47₹39.67₹39.67 +615%
Book Value per Share₹1,453.02₹632.49₹100.61₹222.13₹222.13 +554%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.